Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (Bub1b)
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Parenteral
01
Overview
siRNA (Bub1b) is a small interfering RNA (siRNA) research reagent designed to silence or knock down the BUB1B gene (also known as BubR1, or BUB1 Mitotic Checkpoint Serine/Threonine Kinase B). BUB1B is an essential component of the spindle assembly checkpoint (SAC), which controls chromosome separation during mitosis. By targeting the kinase catalytic center of BUB1B, this siRNA inhibits tumor cell proliferation, colony formation, and tumor growth in vivo, while inducing apoptosis. It has been investigated in preclinical research settings across various cancers, including breast cancer, multiple myeloma, cholangiocarcinoma, prostate cancer, and lung adenocarcinoma. It is exclusively used as a laboratory research tool and is not associated with any clinical development program or commercial brand name.
- Other names
- BUB1B siRNABUB-1B siRNABUB 1B siRNAsiRNA-BUB1BsiRNA-BUB-1BsiRNA-BUB 1B
02
Targets
BUB1B (Mitotic checkpoint serine/threonine-protein kinase BUB1 beta)
Beyond the preview
Go deeper on siRNA (Bub1b).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (Bub1b).